Research concludes WF-OCT allowed for real-time
margin visualization of excised oral and oropharyngeal tissue
without impacting specimen integrity or surgical and pathology
workflows
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF)
(FSE: 4PC) (“Perimeter” or the “Company”) announced the publication
of a peer-reviewed research article in JAMA Otolaryngology—Head and
Neck Surgery. The study’s findings validate the further exploration
of the use of Perimeter’s wide-field Optical Coherence Tomography
(WF-OCT) technology to visualize margins during head and neck
surgeries.
The research study, conducted at Mount Sinai Icahn School of
Medicine, included 53 adult patients undergoing primary ablative
surgery of the oral cavity or oropharynx for squamous cell
carcinoma (SCC). Resected specimens were imaged with Perimeter
S-Series OCT in the operating room prior to routine pathology to
allow for post-operative comparisons.
Arvind K. Badhey, MD, Department of Otolaryngology, University
of Massachusetts Chan Medical School, and lead author, stated, “We
understand that SCC patients with positive margins after initial
surgery are known to have increased risk of local recurrence,
poorer rates of progression-free survival, and a need for adjuvant
treatments such as radiotherapy, chemotherapy and additional
surgery. Our research findings suggest that wide-field OCT may be a
promising adjunct imaging modality for intraoperative visualization
in head and neck surgery, especially at deep margins. Our results
support the further exploration of Perimeter’s technology, with the
hope that this technology could help address this unmet need in SCC
patients.”
Brett A. Miles, DDS MD, Professor and Chair Otolaryngology Head
and Neck Surgery Lenox Hill Hospital New York, and senior author,
commented, “Novel technologies that have potential to improve our
ability to determine surgical margins are needed in order to
improve outcomes in head and neck cancer. This work represents a
novel optical coherence imaging approach which has shown promise
for examining margin depth in real-time during surgery for tongue
cancer, and I am excited to be part of this research effort.”
Jeremy Sobotta, Perimeter’s Chief Executive Officer commented,
“This publication further supports the potential use of our
flagship Perimeter S-Series OCT medical imaging technology across
several tissue types, including head and neck surgery. Further,
this clinical research shows that the Perimeter OCT images
correlate to histological results, with a process that does not
interfere with surgical procedures or final pathology. Ultimately,
our hope is that the ‘real-time’ use of our innovative technology
can help improve outcomes for patients.”
About Perimeter Medical Imaging AI, Inc.
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical
Imaging AI (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) is a medical
technology company driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
areas of high unmet medical need. Available across the U.S., our
FDA-cleared Perimeter S-Series OCT system provides real-time,
cross-sectional visualization of excised tissues at the cellular
level, with 10x greater image resolution than X-ray and ultrasound,
and 100x greater than MRI. The breakthrough-device-designated
investigational Perimeter B-Series OCT with ImgAssist AI represents
our next-generation artificial intelligence technology that is
currently being evaluated in a pivotal clinical trial, with support
from a grant of up to US$7.4 million awarded by the Cancer
Prevention and Research Institute of Texas. The company’s ticker
symbol “PINK” is a reference to the pink ribbons displayed during
Breast Cancer Awareness Month.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking Statements
This news release contains statements that constitute
“forward-looking information” within the meaning of applicable
Canadian securities legislation. In this news release, words such
as “may,” “would,” “could,” “will,” “likely,” “believe,” “expect,”
“anticipate,” “intend,” “plan,” “estimate,” and similar words and
the negative form thereof are used to identify forward-looking
statements. Forward-looking information may relate to management’s
future outlook and anticipated events or results and may include
statements or information regarding the future financial position,
business strategy and strategic goals, competitive conditions,
research and development activities, projected costs and capital
expenditures, research and clinical testing outcomes, taxes and
plans and objectives of, or involving, Perimeter. Without
limitation, information regarding the potential benefits of
Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter
ImgAssist; Perimeter’s expected development activities, future uses
of Perimeter’s WF-OCT technology in relation to head and neck
surgeries, and the expected details regarding Perimeter’s ongoing
clinical trials are forward-looking information. Forward-looking
statements should not be read as guarantees of future performance
or results, and will not necessarily be accurate indications of
whether, or the times at or by which, any particular result will be
achieved. No assurance can be given that any events anticipated by
the forward-looking information will transpire or occur.
Forward-looking information is based on information available at
the time and/or management’s good-faith belief with respect to
future events and are subject to known or unknown risks,
uncertainties, assumptions, and other unpredictable factors, many
of which are beyond Perimeter’s control. Such forward-looking
statements reflect Perimeter’s current view with respect to future
events, but are inherently subject to significant medical,
scientific, business, economic, competitive, political, and social
uncertainties and contingencies. In making forward-looking
statements, Perimeter may make various material assumptions,
including but not limited assumptions related to (i) the accuracy
of Perimeter’s financial projections; (ii) obtaining positive
results from trials; (iii) obtaining necessary regulatory
approvals; and (iv) general business, market, and economic
conditions. Further risks, uncertainties and assumptions include,
but are not limited to, those applicable to Perimeter and described
in Perimeter’s Management Discussion and Analysis for the year
ended December 31, 2021, which is available on Perimeter’s SEDAR
profile at www.sedar.com, and could cause actual events or results
to differ materially from those projected in any forward-looking
statements. Perimeter does not intend, nor does Perimeter undertake
any obligation, to update or revise any forward-looking information
contained in this news release to reflect subsequent information,
events, or circumstances or otherwise, except if required by
applicable laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221205005252/en/
Chris Scott Chief Financial Officer Perimeter Medical Imaging
AI, Inc. Investors: investors@perimetermed.com Toll-free:
888-988-7465 (PINK)
Jodi Regts Corporate Communications Perimeter Medical Imaging
AI, Inc. Media: media@perimetermed.com Mobile: 469-743-1834
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Mar 2025 a Abr 2025
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Abr 2024 a Abr 2025
